Johnson & Johnson Innovative Medicine
Johnson & Johnson Innovative Medicine, a division of the renowned Johnson & Johnson family, is headquartered in the United States and operates extensively across major global regions, including Europe and Asia. Founded in 1886, the company has established itself as a leader in the pharmaceutical industry, focusing on innovative solutions in areas such as immunology, oncology, neuroscience, and infectious diseases.
With a commitment to advancing healthcare, Johnson & Johnson Innovative Medicine offers a diverse portfolio of core products, including biologics and advanced therapies that are distinguished by their efficacy and safety profiles. The company has achieved significant milestones, including numerous FDA approvals and groundbreaking research initiatives, solidifying its position as a trusted name in the market. Through its dedication to innovation and patient care, Johnson & Johnson continues to make a profound impact on global health.
+38 vs industry average
Johnson & Johnson Innovative Medicine’s score of 76 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Johnson & Johnson Innovative Medicine?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Johnson & Johnson Innovative Medicine yet.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Johnson & Johnson Innovative Medicine’s Climate Goals (2030 & 2050)
1 goal2045
44% reduction in scope 3 downstream
Janssen have committed to reaching net-zero emissions from the site by 2045 and have an interim target of a 44% reduction in absolute Scope…
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 1 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative
Inherited from Johnson & Johnson
Carbon Disclosure Project
Inherited from Johnson & JohnsonThe Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Inherited from Johnson & JohnsonClimate Action 100
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project